| ²é¿´: 1236 | »Ø¸´: 3 | |||
| ¡¾Óн±½»Á÷¡¿»ý¼«»Ø¸´±¾Ìû×Ó£¬²ÎÓë½»Á÷£¬¾ÍÓлú»á·ÖµÃ×÷Õß ivers12 µÄ 9 ¸ö½ð±Ò | |||
ivers12Ìú¸Ëľ³æ (СÓÐÃûÆø)
|
[½»Á÷]
»ùÒò¶¾ÐÔÔÓÖÊÑо¿
|
||
|
Çë½ÌÒ»¸öÎÊÌ⣺ Èç¹ûÒ©µäÖеÄij¸öÒÑÖªÔÓÖÊ£¬º¬ÓкÍAPI²»Í¬µÄ¾¯Ê¾½á¹¹£¬ÊÇ·ñÐèÒª°´ÕÕ»ùÒò¶¾ÐÔÔÓÖÊÑо¿£¨ÕâÀïÔݲ»ÌÖÂÛÊÇ·ñÐèÒªÈí¼þÔ¤²â£¬Ö»¿´¾¯Ê¾½á¹¹£© ·ÖΪÁ½ÖÖÇé¿ö£º 1¡¢Ò©µäÖÐÃ÷È·¸ÃÔÓÖʵÄÏÞ¶È 2¡¢Ò©µäÖÐδÃ÷È·¸ÃÔÓÖʵľßÌåÏÞ¶È Ó¦¸ÃÈçºÎ´¦ÀíÄØ£¿ |
» ²ÂÄãϲ»¶
ÈçºÎ¸ßЧµÄ²âÁ¿ÏÙ²¡¶¾µÄÁ£¾¶ºÍµçλ
ÒѾÓÐ0È˻ظ´
26ÔÚÖ°É격¡ªÉúÎïÓëÒ½Ò©¡ª¿¹Ìå/ADCÒ©Îï·½Ïò£¬½Õ㻦£¬ÓÐÏîÄ¿£¬¿É´ø×Ê¡£
ÒѾÓÐ1È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ293È˻ظ´
288·ÖÇóµ÷¼Á
ÒѾÓÐ0È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§Ôº×ÔÉíÃâÒß²¡¿ÎÌâ×éÕÐÊÕ»ù´¡Ò½Ñ§Ïà¹Ø×¨ÒµµÄµ÷¼ÁÑо¿Éú
ÒѾÓÐ2È˻ظ´
Ò»Ö¾Ô¸ËÕÖÝ´óѧ ÉúÎï¼¼ÊõÓ빤³Ì£¨086001£© ³õÊÔ323·Ö£¬Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÈýÄêʵÑéÊÒ¹¤×÷¾Àú£¬Ò»Ö¾Ô¸»ªÖÐũҵ´óѧ΢ÉúÎ×Ü·Ö288Çóµ÷¼Á
ÒѾÓÐ2È˻ظ´
070700Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
Çóµ÷¼Á×Ü·Ö327
ÒѾÓÐ1È˻ظ´

Alian2013
ͳæ (³õÈëÎÄ̳)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 268.8
- Ìû×Ó: 17
- ÔÚÏß: 18.5Сʱ
- ³æºÅ: 2318463
- ×¢²á: 2013-03-04
- ÐÔ±ð: MM
- רҵ: É«Æ×·ÖÎö
¡ï ¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ivers12: ½ð±Ò+1 2022-01-24 13:18:10
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ivers12: ½ð±Ò+1 2022-01-24 13:18:10
| ÔÓÖÊ»¹ÓкÍAPI²»Í¬µÄ»ùÒò¶¾¾¯Ê¾½á¹¹£¬Ó¦¸Ã°´M7ÖеĵÚÈýÖÖÇé¿ö½øÐлùÒò¶¾Ñо¿£¬ÈçÈôICH¸ø³öÔÓÖÊÏÞ¶È£¬¿É°´ÕÕ¸ø³öµÄÏÞ¶ÈÑо¿£¬ÈçÈôûÓиø³öÔÓÖÊÏÞ¶È£¬¿ÉÒÔ¸ù¾ÝICH¸ø³öµÄʹÓÃʱ¼äÖÜÆÚ¶ÔÓ¦µÄPDEºÍ×î´óÓÃÒ©Á¿¼ÆË㣬Ҳ¿ÉÒÔ°´ÕÕ1.5ug/ÌìµÄPDEÓÃÒ©Ñо¿£¬·çÏÕ×îµÍ¡£ |

2Â¥2022-01-18 15:36:10
ivers12
Ìú¸Ëľ³æ (СÓÐÃûÆø)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 8769.6
- É¢½ð: 1
- Ìû×Ó: 259
- ÔÚÏß: 137.9Сʱ
- ³æºÅ: 3257324
- ×¢²á: 2014-06-05
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É
|
±ÈÈçÕâ¸öBPÖеģº Limits: ¡ª impurity A: maximum 0.2 per cent; ¡ª impurity F: maximum 0.15 per cent; ¡ª unspecified impurities: for each impurity, maximum 0.10 per cent; ¡ª total: maximum 0.4 per cent; ¡ª reporting threshold: 0.05 per cent. Specified impurities A, F. Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other/unspecified impurities and/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) B, C, D, E. ÕâÖÖÇé¿öÏ£¬ÔÓÖÊA£¬ÔÓÖÊF£¬ºÍÔÓÖÊB£¨º¬¾¯Ê¾½á¹¹£©µÄÏÞ¶ÈÈçºÎ½ç¶¨£¿ |

3Â¥2022-01-27 13:32:03
mrzhl1986
½ð³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 211 (´óѧÉú)
- ½ð±Ò: 1258.4
- É¢½ð: 264
- ºì»¨: 13
- ɳ·¢: 4
- Ìû×Ó: 1020
- ÔÚÏß: 411.2Сʱ
- ³æºÅ: 1019119
- ×¢²á: 2010-05-15
- ÐÔ±ð: GG
- רҵ: ÓлúºÏ³É

4Â¥2022-02-08 17:38:39














»Ø¸´´ËÂ¥